| Market Capitalization (Millions $) |
50 |
| Shares
Outstanding (Millions) |
37 |
| Employees |
25 |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
-41 |
| Cash Flow (TTM) (Millions $) |
-3 |
| Capital Exp. (TTM) (Millions $) |
0 |
Pds Biotechnology Corp
Pds Biotechnology Corp is a clinical-stage biotechnology company located in New Jersey, USA, founded in 200 The company aims at developing immunotherapy-based treatments for cancer and infectious diseases by using its unique Versamunee platform technology.
The Versamunee platform technology combines lipids with peptides to produce an immunostimulatory molecule that effectively triggers and augments T-cell responses against specific antigens. This mechanism of action renders Versamunee an excellent candidate as an immunotherapeutic vaccine adjuvant for combating both solid tumor and viral indications.
The company's pipeline includes multiple immunotherapeutic products in clinical development for the treatment of head and neck cancer, prostate cancer, human papillomavirus (HPV)-associated cancers, and COVID-19. Its lead candidate, PDS0101, is a cancer immunotherapy that uses Versamunee as an adjuvant to elicit a potent anti-tumor T-cell response.
In December 2020, Pds Biotechnology announced positive interim results from a Phase 2 trial of PDS0101 in combination with Keytrudae (pembrolizumab) for the treatment of HPV-positive head and neck cancer. The company reported excellent response rates, with an objective response rate of 67% in patients who had failed previous treatment with chemotherapy and radiation.
Pds Biotechnology has also developed PDS0203, a COVID-19 vaccine candidate, using Versamunee as an adjuvant. The vaccine candidate has shown promising preclinical results, with a strong immune response against SARS-CoV-2 in animal models.
In addition to these clinical and preclinical assets, Pds Biotechnology has entered into partnerships with larger pharmaceutical companies, such as Merck & Co, for the clinical development of its immunotherapeutic products. These partnerships provide additional financial resources and research expertise to the company, further advancing its clinical portfolio.
Overall, Pds Biotechnology is leading the charge in developing innovative immunotherapies that have the potential to revolutionize cancer and infectious disease treatment. With its robust pipeline and proven Versamunee platform technology, the company is well-positioned to make significant strides in the biotechnology industry in the coming years.
Company Address: 303A College Road East Princeton 8540 NJ
Company Phone Number: 208-3343 Stock Exchange / Ticker: NASDAQ PDSB
|
1.71%